Indivumed GmbH generates, characterizes and analyzes highly standardized biological samples from human cancer patients under ISO-9001:2008 standards. The company inte-grates a unique infrastructure of proprietary clinical and laboratory facilities with an outstand-ing biospecimen biobank of more than 15,000 patient-cases. Indivumed offers a broad range of research services including immunohistochemistry services, drug profiling applying prima-ry tumor cultures, a comprehensive biobank portfolio and further research services with a special focus on cancer related signaling molecules and pathway activity. In addition, Indi-vumed pursues biomarker discovery programs for cancer.
The company is headquartered in Hamburg, Germany, with a subsidiary in Baltimore, MD (USA).